Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Queen's University in Kingston Stories

2012-06-21 02:26:13

CALGARY, June 21, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that it has entered into an agreement whereby the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN(®) in patients with advanced or metastatic breast cancer. "We are excited to announce our fourth randomized study with the NCIC CTG," said Dr. Brad Thompson, President...

2012-06-05 02:27:45

--Company to Host Conference Call to Discuss Randomized Phase II Program-- CALGARY, June 5, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN(®) in patients with advanced or metastatic non-small cell lung cancer ("NSCLC"). "This agreement...

2012-05-03 02:31:45

CALGARY, May 3, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN(®) in patients with advanced or metastatic colorectal cancer. "We are pleased to be conducting a second randomized study with the NCIC CTG," said Dr. Brad Thompson, President and...

2012-02-21 06:00:00

CALGARY, Feb. 21, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN(®) in patients with recurrent or metastatic castration resistant prostate cancer. "Third party sponsored trials remain an important part of our overall clinical strategy. We...

2011-09-12 07:05:00

SEATTLE, WA, Sept. 12, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway. The open label Phase 2 trial is being conducted by the NCIC Clinical Trials Group...

2008-09-15 06:00:17

WELLESLEY, Mass., Sept. 15 /PRNewswire/ -- Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced that Queen's University in Kingston, Ontario, Canada, is the latest high-profile institution to implement Xceed's Ziplex System as a critical tool to advance its translational research. Harriet Feilotter, Ph.D., FCCMG, of the University's Department of Pathology and Molecular Medicine, is the principal investigator of a study that...